InsightRX's Participation at ASHP 2024 Midyear Clinical Meeting
InsightRX, a prominent leader in Bayesian model-informed precision dosing (MIPD) software, is excited to participate in the ASHP 2024 Midyear Clinical Meeting & Exhibition as both an exhibitor and presenter. The event is set to take place at the Ernest N. Morial Convention Center, and InsightRX representatives will be available at booth 1340.
Event Overview and InsightRX Presentation
The ASHP meeting, organized by the American Society of Health-System Pharmacists, will feature a range of activities including vendor exhibits, educational sessions, and valuable networking opportunities tailored for pharmacy professionals. InsightRX will present significant updates regarding their innovative products and solutions during the event.
A highlight of the exhibition includes a poster presentation by InsightRX's Senior Director of Product & Customer Experience, Dr. Jonathan Faldasz, scheduled for a pivotal time on the afternoon of Monday, Dec. 9. This poster will discuss the research titled "Proposed Update to the Cockcroft-Gault Equation for Patients with Low Serum Creatinine: Results from a Massive Multi-Site Dataset," which reflects InsightRX's commitment to advancing clinical practices.
Study Findings on Renal Function Estimation
The research conducted by InsightRX evaluates the Cockcroft-Gault equation, widely recognized as the benchmark for estimating renal function in patients with low serum creatinine levels. The team analyzed data from nearly 100,000 patients to reveal inaccuracies in this traditional method. The study reveals the development of a modified equation that significantly enhances predictive accuracy, thus benefiting clinical practice.
Showcasing the New InsightRX Gemini Feature
One of the exciting features being showcased at the ASHP 2024 is the new addition to the Nova platform known as InsightRX Gemini. This tool is designed to simplify the complexities associated with manual PK model selection by automatically identifying the optimal pharmacokinetic model based on common patient factors.
Comparative Advantages of InsightRX Gemini
The Gemini feature has emerged from an extensive analysis of around 400,000 vancomycin treatment courses. When assessed against commonly available PK models, Gemini boasts several advantages:
- It increases dosing accuracy for individual patients by up to 47.2%.
- It improves precision by as much as 25%.
- It reduces bias significantly, by up to 93%.
Expansion of Bayesian MIPD Across Therapeutic Areas
In recent times, MIPD dosing practices have gained traction across various therapeutic domains, promising an evolution in workflows that enhances accuracy and patient outcomes. Beyond vancomycin, InsightRX provides numerous drug modules that tackle diverse therapeutic needs. Some of the highlighted therapeutic areas include antifungal therapy, beta-lactam optimization, and personalized dosing strategies for transplant patients.
Insights into Other Drug Modules
Several topics have been discussed in detail, illustrating the application and benefits of model-informed dosing:
- Antifungals: The validation of an MIPD strategy for posaconazole underscores the importance of individualized dosing for effective patient outcomes.
- Beta-lactams: Addressing the challenges with TDM for beta-lactams reveals opportunities to elevate patient management through optimized antibiotic doses.
- Solid Organ Transplant: Insights indicate that Bayesian estimation can enhance current practices in tacrolimus therapeutic monitoring.
- Bone Marrow Transplant: Research demonstrates that individual dose personalization for busulfan can lead to better patient outcomes.
- Anticoagulants: Recent advances in MIPD are expected to significantly improve heparin therapy personalization, addressing critical care needs.
- Inflammatory Bowel Disease: Population PK modeling is being explored for infliximab, enhancing treatment effectiveness for children.
Looking Ahead: Insights on Future Growth
As InsightRX heads into the ASHP meeting, CEO Sirj Goswami expressed enthusiasm for the journey the company has experienced over the past year, filled with accomplishments and growth. InsightRX remains dedicated to enhancing dosing safety and accuracy through model-informed precision dosing. This approach not only aims to address current clinical needs but also seeks to improve operational efficiency and patient outcomes in the long run.
Frequently Asked Questions
What is InsightRX?
InsightRX is a healthcare technology company that provides a cloud-based platform for clinical decision support, enhancing therapeutic decisions across patient care.
What is Bayesian MIPD?
Bayesian Model-Informed Precision Dosing (MIPD) utilizes patient-specific data to optimize drug dosing, improving treatment outcomes and minimizing adverse effects.
What will InsightRX present at the ASHP meeting?
InsightRX will showcase updates on their platform, present research findings on renal function estimation, and feature demonstrations of their new Gemini tool.
How does InsightRX Gemini improve dosing accuracy?
Gemini enhances dosing accuracy by automatically selecting the most suitable PK model based on multiple patient factors, increasing precision and reducing bias.
What are the applications of InsightRX's modules?
InsightRX's modules cover a wide range of therapeutic areas including antifungals, beta-lactams, and transplant medications, with a focus on personalized dosing strategies.
